Table 7 Therapy and outcome of ITP with hyperlipidemia stratified by statin therapy
From: Hyperlipidemia in immune thrombocytopenia: a retrospective study
|  | With statin treatment (n = 17) | Without statin treatment (n = 86) | P value |
|---|---|---|---|
Age (years) (median, interquartile range) | 62 (16) | 58 (10.75) | 0.0651 |
Gender(male %) | 7 (41.2%) | 31 (36.0%) | 0.692 |
ITP duration (months) (mean ± SEM) | 46.53 ± 21.69 | 51.91 ± 8.93 | 0.804 |
Initial platelet counts (×109/L) (mean ± SEM) | 42.18 ± 14.7 | 16.90 ± 2.04 | 0.0022** |
Platelet counts after treatment (×109/L) (mean ± SEM) | 81.36 ± 12.29 | 74.59 ± 7.44 | 0.72 |
LDL-C (mmol/L) (mean ± SEM) | 2.75 ± 0.25 | 3.30 ± 0.10 | 0.0394* |
HDL-C (mmol/L) (mean ± SEM) | 1.04 ± 0.08 | 1.23 ± 0.04 | 0.076 |
TC (mmol/L) (mean ± SEM) | 4.65 ± 0.27 | 5.22 ± 0.13 | 0.073 |
TG (mmol/L) (mean ± SEM) | 2.36 ± 0.35 | 1.92 ± 0.14 | 0.23 |
Severe bleeding (n, %) | 0 (0%) | 30 (34.9%) | 0.02* |
Corticosteroid treatment (R, %) | 12 (100.0%) | 49 (66.2%) | 0.016* |
TPO agent treatment (R, %) | 6 (85.7%) | 28 (50.9%) | 0.116 |
Refractory (n, %) | 0 (0%) | 14 (16.3%) | 0.066 |